Dr. Brody on Tolerability of In-Situ Vaccines in Indolent Non-Hodgkin Lymphoma
April 16th 2020Joshua Brody, MD, discusses the utility of in-situ vaccines as a novel way to harness immune response and extend the reach of immunotherapy in patients with advanced-stage indolent non-Hodgkin lymphoma.
Read More
Dr. Brody Discusses Exciting Therapies for Lymphomas and CLL
November 24th 2014Joshua Brody, MD, assistant professor, Icahn School of Medicine, director, Lymphoma Immunotherapy Program, Mount Sinai Hospital, discusses exciting new therapies for lymphomas and chronic lymphocytic leukemia (CLL).
Read More